Saint-Laurent 11/21/2012 2:36:11 PM
MethylGene Inc. (Stock Symbol: CA: MYG) is now on LinkMyStock.com
MethylGene Inc.(Stock Symbol: CA: MYG) has joined LinkMyStock.com. Now Stock Brokers, Brokerage Firms and Investors/Shareholders from around the world who follow MethylGene Inc. can link directly to MethylGene Inc. Link My Stock Hub. Brokers and Brokerage Firms that link to MethylGene Inc. typically are familiar with the company and can facilitate transactions in MethylGene Inc. security. Investors linking to MethylGene Inc. usually are either existing shareholders looking to stay informed when MethylGene Inc. posts new information or people that are simply interested in MethylGene Inc. that are not yet or may never become shareholders.
LinkMyStock is a premier financial networking platform designed specifically for public companies, brokerage firms, brokers and investors. LinkMyStock.com provides a network that consists of brokers, brokerage firms and investors that can link directly to the companies that they follow. With brokers from around the world having the ability to select companies to link to that are members of Link My Stock this provides investors with the ability to locate brokers and contact them to find out more information about a company they are interested in learning more about.
LinkMyStock.com provides every member with their own hub where they post content. Content sections include; press releases, blogs, pictures, videos, Right Now status updates, events, jobs and more in order to attract more visitors and increase the number of search results along with improving indexing.
To link to the MethylGene Inc.'s Link My Stock Hub sign into your Link My Stock Hub or Join Link My Stock today.
About MethylGene Inc.
MethylGene Inc. is a publicly-traded biopharmaceutical company that is developing novel targeted drugs for the treatment of cancer and infectious disease. The Company is focused on its two lead molecules, MGCD265 for cancer and MGCD290 for fungal infections; both are currently in human clinical trials. While MethylGene has discovered an impressive pipeline of molecules through its expertise in molecular biology and chemistry, it has chosen to focus on MGCD265 and MGCD290. We believe that these are both highly promising and differentiated product candidates. MethylGene has additional products in its pipeline which also have the potential to address current medical needs.
